Edition:
United States

Alexion Pharmaceuticals Inc (ALXN.O)

ALXN.O on Nasdaq

121.06USD
9:30am EDT
Change (% chg)

$1.00 (+0.83%)
Prev Close
$120.06
Open
$120.11
Day's High
$121.06
Day's Low
$120.11
Volume
19,177
Avg. Vol
1,813,866
52-wk High
$193.45
52-wk Low
$110.56

ALXN.O

Chart for ALXN.O

About

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company's marketed products... (more)

Overall

Beta: 1.34
Market Cap(Mil.): $26,923.21
Shares Outstanding(Mil.): 224.25
Dividend: --
Yield (%): --

Financials

  ALXN.O Industry Sector
P/E (TTM): 304.06 37.66 37.54
EPS (TTM): 0.39 -- --
ROI: 0.73 14.54 13.98
ROE: 1.07 15.32 14.88

BRIEF-Alexion gets orphan drug designation for ALXN1007

* European Commission grants orphan drug designation to ALXN1007 for the treatment of patients with graft-versus-host disease (GVHD)

Aug 29 2016

BRIEF-Alexion Pharmaceuticals-FDA recently completed routine current good manufacturing practice inspection of Co's Smithfield, Rhode Island Manufacturing Facility

* Fda recently completed routine current good manufacturing practice inspection of Co's Smithfield, Rhode island manufacturing facility

Aug 08 2016

BRIEF-Alexion reports Q2 non-gaap EPS $1.13

* FY2016 earnings per share view $5.05, revenue view $3.06 billion -- Thomson Reuters I/B/E/S

Jul 28 2016

U.S. RESEARCH ROUNDUP-D.R. Horton, Humana, Chicago Bridge & Iron

July 22 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adeptus Health, Chipotle Mexican Grill and Yadkin Financial, on Friday. HIGHLIGHTS * Chicago Bridge & Iron Co : Baird cuts to neutral * D.R. Horton Inc : BofA Merrill cuts to neutral from buy * Humana Inc : Wolfe Research raises to outperform * Community Bank System Inc : Sandler O'Neill cuts to

Jul 22 2016

BRIEF-Alexion presents new SBC-103 data in patients with MPS iiiB

* Alexion presents new SBC-103 (Rhnaglu enzyme) phase 1/2 data on brain MRI and neurocognitive assessments in patients with mucopolysaccharidosis iiib (MPS IIIB)

Jul 14 2016

BRIEF-Alexion Pharmaceuticals announces data from phase 1/2 study of ALXN1210

* Late-Breaking data presented at EHA: all patients with pnh treated with once-monthly dosing of ALXN1210 in phase 1/2 study exhibit rapid and sustained reductions in ldhSays announced today that interim data were presented from a phase 1/2 study of ALXN1210

Jun 10 2016

US STOCKS-S&P edges closer to record high; energy shares lead

* Dow up 0.1 pct, S&P up 0.1 pct, Nasdaq down 0.1 pct (Updates to close)

Jun 07 2016

US STOCKS-S&P edges closer to record high; energy shares lead

* Dow up 0.3 pct, S&P up 0.3 pct, Nasdaq down 0.04 pct (Updates to late afternoon)

Jun 07 2016

Alexion shares slump as drug misses goal in late-stage trial

Alexion Pharmaceuticals Inc said its drug Soliris, already approved in the United States for the treatment of two rare blood disorders, missed its primary goal in a late-stage trial.

Jun 06 2016

UPDATE 1-Alexion shares slump as drug misses goal in late-stage trial

June 6 Alexion Pharmaceuticals Inc said its drug Soliris, already approved in the United States for the treatment of two rare blood disorders, missed its primary goal in a late-stage trial.

Jun 06 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.